31 results about "Cell division cycle" patented technology

The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and / or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B) or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.

The invention belongs to the field of chemical pharmaceuticals, and more specifically relates to 7-oxy, thio or imino substituted coumarin with a structure represented by formula 8 or 12, and derivatives and antineoplastic activity thereof. The results of antineoplastic activity and pharmacological target experiments show that 7-oxy, thio or imino substituted coumarin derivatives possess inhibitory activity on the growth of nasopharyngeal carcinoma cells and drug-resistant tumor strains of nasopharyngeal carcinoma cells, lung cancer cells and prostatic cancer cells; and the results of pharmacological research show that 7-oxy, thio or imino substituted coumarin is capable of promoting cell apoptosis and influencing cell division cycle G2 / M. 7-oxygen, sulfur or nitrogen substituted coumarin is novel in structure, and is capable of providing basis for intensive study on target sports and related pharmacological mechanisms such as reversing drug-resistance mechanism. X is selected from oxygen, sulfur or nitrogen atoms; R2 is selected from alkyl, alkoxy, halogenated alkyl groups or ester group; and R3 is selected from alkyl, and substituted aromatic heterocyclic compounds including 6-chloropyridine and substituted aralkyl.

The invention discloses a brown planthopper N1cdc2 gene as well as an encoding product and an application of the brown planthopper N1cdc2 gene, and belongs to the technical field of biology. On the one hand, the invention discloses a brown planthopper N1cdc2 gene sequence and an encoding protein amino acid sequence of the brown planthopper N1cdc2 gene, and on the other hand, the invention also discloses an application of the brown planthopper N1cdc2 gene in control of the survival rate and the reproductive capacity of brown planthopper. Research is carried out mainly aiming at a cell division cycle gene N1cdc2 which is related to brown planthopper reproduction, the expression pattern and related function of the gene in brown planthopper reproduction expression are ascertained, the potential of the brown planthopper N1cdc2 gene as a new target for preventing an injurious insect is defined, and a foundation is established for development of an N1cdc2-based pest control new strategy.

The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

The invention discloses a novel purine analogue 7-amino-tetrazole[1,5-a]pyrimidine-5-alcohol(compound II) and its synthetic route. It shows through a pharmacological experiment that the compound II has an effect of inhibiting cell division cycle phosphoesterase CDC25. The compound II can be used as an antimetabolic medicine with high biological activity, good selectivity and little toxicity, and can be widely used in clinic.

The present invention relates to novel substituted [5,6]cyclo-4(3H)-pyrimidinone compounds of formula (I) and methods for their preparation. (I) In particular, the present invention relates to novel substituted [5,6]cyclo-4(3H)-pyrimidinone compounds useful as protein kinase inhibitors, especially CDC7 (Cell Division Cycle 7) inhibitors.

The invention relates to modulating Cdc14B levels (cell division cycle 14 homolog B) and / or Cdh1 (Fzr1 protein, CDC20-like 1b, or fizzy-related protein) levels to sensitize cells to DNA damage by increasing the abundance of Plk1 (polo-like kinase 1) in a target cell. In certain embodiments, the invention relates to modulating Plk1 levels, and in particular to increasing Plk1 levels, to sensitize target cells such as cancer cells to cell death or apoptosis. In certain embodiments, the invention relates to inhibitors of Cdc14B and Cdh1 that sensitize tumor cells to chemotherapy or radiation induced cell death or apoptosis. In addition to applications relating to cancer therapies and diagnostics, the Plk1 modulators and assays will be employed for identifying novel drugs or drug candidates useful for various proliferative and / or differentiative disorders such as major opportunistic infections, immune disorders, cardiovascular diseases and inflammatory disorders.

Provided is a rabbit monoclonal antibody to acetylated mouse BubR1 and a preparation method therefor and, more particularly, provides the use of the monoclonal antibody in a method for measuring the activity of cell division checkpoints on the basis of a degree of acetylation of BubR1, a method for detecting a tumor disease on the basis of aberrant cell division, a method for diagnosing cancer, a method for screening anti-cancer agents, or a method for regulating a cell division cycle.